Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $19.15M fell 20.6% year over year, behind the -7.8% change in trailing-twelve-month research & development. Sequentially, it fell 18.9% from the prior quarter. Over 3 fiscal years it compounded at -12.9% a year.

Context

  • Research & development amounted to 33.9% of revenue in FY2025, down 23.7 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.6% toward the trailing-twelve-month pace of -7.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.15M-18.9% QoQ
Last fiscal yearDec 2025
$93.77M-8.9% YoY
LTMJun 2026
$88.21M-7.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.6%——
1 year-8.9%——
3-year CAGR-12.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
93.77M USD
Year-over-year change
-8.9%
4-year CAGR
-9.9%

Research & Development vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 research & development of $88.21M is the 9th highest of the 10 companies compared; the peer median is $236.92M.
  • Its year-over-year change of -7.8% is the 8th highest of 10, against a peer median of +3.2%.
  • Research & development amounts to 28.6% of revenue for ADPT, versus a peer median of 52.7%.
ADPT Competitors Peer median
Research & Development for ADPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BEAMBeam Therapeutics Inc.LTM Jun 2026$408.66M +3.1%+9.5%261.9%
LEGNLegend Biotech CorporationLTM Sep 2026$378.58M -9.4%+7.3%27.9%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$339.54M +5.2%+52.0%150.7%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$301.59M +72.6%+71.3%—
ZLABZai Lab LimitedLTM Jun 2026$236.92M +3.2%-8.3%52.7%
SRRKScholar Rock Holding CorporationLTM Sep 2026$211.05M -0.0%+18.8%37026.5%
IRONDisc Medicine, Inc.LTM Sep 2026$183.14M +22.7%+72.2%—
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$115.59M +83.0%+14.7%16.9%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$88.21M -7.8%-12.9%28.6%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$11.48M -17.7%-13.7%1.9%
Peer median (excluding ADPT) $236.92M+3.2%+14.7%52.7%

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue154.34M185.31M170.28M178.96M276.98M
Cost of Revenue49.3M57.91M75.55M72.08M71.36M
Gross Profit105.04M127.4M94.72M106.88M205.62M
Gross Margin68.1%68.7%55.6%59.7%74.2%
Research & Development142.34M141.76M122.12M102.95M93.77M
Selling, General & Admin169.97M184.13M172.51M157.57M167.27M
Operating Expenses314.01M327.59M321.76M269.43M262.74M
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
EBITDA(193.35M)(175.21M)(189.27M)(128.76M)(29.85M)
EBITDA Margin-125.3%-94.6%-111.2%-71.9%-10.8%
Operating Income(208.97M)(200.19M)(227.04M)(162.55M)(57.12M)
Operating Margin-135.4%-108.0%-133.3%-90.8%-20.6%
Interest Income1.67M4.06M15.53M14.53M9.44M
Interest Expense04.24M13.8M11.58M11.78M
Other Income / Expenses1.67M(182K)1.73M2.95M(2.33M)
Income Before Tax(207.3M)(200.37M)(225.3M)(159.6M)(59.46M)
Pre-Tax Margin-134.3%-108.1%-132.3%-89.2%-21.5%
Income Tax Expense00000
Net Income(207.28M)(200.19M)(225.25M)(159.49M)(59.5M)
Net Margin-134.3%-108.0%-132.3%-89.1%-21.5%
EPS (Basic)(1.46)(1.00)(1.56)(1.08)(0.39)
EPS (Diluted)(1.46)(1.00)(1.56)(1.08)(0.39)
Weighted Avg Shares140.35M142.52M144.38M147.1M151.72M
Weighted Avg Shares (Diluted)140.35M142.52M144.38M147.1M151.72M

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.